Literature DB >> 19324960

Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus.

Duckhyang Shin1, Hyeon Lee, Soo In Kim, Yeup Yoon, Meehyein Kim.   

Abstract

RNA interference (RNAi)-based gene silencing possesses great therapeutic potential for inhibiting replication of human viruses such as hepatitis C virus (HCV). However, one of the putative limitations for its use as a therapy is the rapid emergence of escape variants. These contain deletions or mutations within the viral genome sequences complementary to the small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) being used for treatment. As a potential solution to this problem, we constructed an expression system for duplex RNAs harboring two siRNA units using convergent H1 and U6 Pol III promoters. Here, the length and orientation of the transcript, tandem siRNA (tsiRNA), were optimized to be processed by the intracellular ribonuclease Dicer into functional siRNAs targeting different sequences. Assessment in transfected cells indicates that the length of the tsiRNA duplex (40-42 base pairs) is more critical for both siRNA-producing capacity and gene silencing activity than the orientation of each siRNA unit. In Huh7 cells replicating full-length HCV RNA, expression of length-optimized tsiRNA inhibited viral protein levels as efficiently as a single 21-nucleotide siRNA-expression construct, without affecting miRNA maturation or induction of an interferon response. We verified that the anti-viral activity of tsiRNA was achieved by precise cleavage of two target sites. A distinct advantage of this strategy is that each side of the optimized linear duplex RNA could enter into the Dicer-mediated processing machinery, thus likely providing more equal and efficient production of multiple siRNAs required for reducing the chance of viral escape.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324960      PMCID: PMC2673075          DOI: 10.1261/rna.1268209

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  35 in total

Review 1.  Replication of hepatitis C virus.

Authors:  R Bartenschlager; V Lohmann
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

2.  Interactions between double-stranded RNA regulators and the protein kinase DAI.

Authors:  L Manche; S R Green; C Schmedt; M B Mathews
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

Review 3.  siRNAs: applications in functional genomics and potential as therapeutics.

Authors:  Yair Dorsett; Thomas Tuschl
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

5.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Functional and intracellular localization properties of U6 promoter-expressed siRNAs, shRNAs, and chimeric VA1 shRNAs in mammalian cells.

Authors:  Nan Sook Lee; Daniel H Kim; Jessica Alluin; Marjorie Robbins; Shuo Gu; Haitang Li; James Kim; Paul M Salvaterra; John J Rossi
Journal:  RNA       Date:  2008-08-12       Impact factor: 4.942

7.  Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.

Authors:  Glen A Coburn; Bryan R Cullen
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.

Authors:  Olivier ter Brake; Karen 't Hooft; Ying Poi Liu; Mireille Centlivre; Karin Jasmijn von Eije; Ben Berkhout
Journal:  Mol Ther       Date:  2008-01-15       Impact factor: 11.454

10.  Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region.

Authors:  Joyce A Wilson; Christopher D Richardson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

View more
  13 in total

1.  RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control.

Authors:  Carine L Holz; Emmanuel Albina; Cécile Minet; Renaud Lancelot; Olivier Kwiatek; Geneviève Libeau; Renata Servan de Almeida
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.

Authors:  Dirk Grimm
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

3.  Dual MicroRNA to Cellular Prion Protein Inhibits Propagation of Pathogenic Prion Protein in Cultured Cells.

Authors:  Sang-Gyun Kang; Chiye Kim; Judd Aiken; Han Sang Yoo; Debbie McKenzie
Journal:  Mol Neurobiol       Date:  2017-03-29       Impact factor: 5.590

Review 4.  Novel RNA-based strategies for therapeutic gene silencing.

Authors:  Christopher R Sibley; Yiqi Seow; Matthew J A Wood
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

5.  Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA.

Authors:  Muhammad Ansar; Usman Ali Ashfaq; Imran Shahid; Muhammad Tahir Sarwar; Tariq Javed; Sidra Rehman; Sajida Hassan; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-05-02       Impact factor: 4.099

6.  Possibilities for RNA interference in developing hepatitis C virus therapeutics.

Authors:  Kristi L Berger; Glenn Randall
Journal:  Viruses       Date:  2010-08-06       Impact factor: 5.818

7.  Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma.

Authors:  Tiejun Li; Yuwen Xue; Guilan Wang; Tingting Gu; Yunlong Li; York Yuanyuan Zhu; Li Chen
Journal:  J Cancer       Date:  2016-06-25       Impact factor: 4.207

Review 8.  Antiviral RNAi: translating science towards therapeutic success.

Authors:  Priya S Shah; David V Schaffer
Journal:  Pharm Res       Date:  2011-08-09       Impact factor: 4.200

9.  Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.

Authors:  Zhongqi Bian; An Xiao; Mingmei Cao; Mingqiu Liu; Shuang Liu; Ye Jiao; Weiyao Yan; Zhongtian Qi; Zhaoxin Zheng
Journal:  Virol J       Date:  2012-11-16       Impact factor: 4.099

10.  Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.

Authors:  Mohube Betty Mowa; Carol Crowther; Abdullah Ely; Patrick Arbuthnot
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.